



Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13 2025, 4:30 PM EDT

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28 2025, 8:30 AM EDT

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15 2025, 4:20 PM EDT

Stock Overview

| | |
|---------------|-----------------|
| Symbol | SCYX |
| Exchange | Nasdaq |
| Market Cap | 34.21m |
| Last Price | \$0.81 |
| 52-Week Range | \$0.66 - \$1.78 |

08/22/2025 07:58 PM EDT

SCYNEXIS, Inc.

1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.